Reidy Christopher R

SEC source: 0000785161-26-000180 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,777

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.

SEC source: 0000785161-26-000180 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,458

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.

SEC source: 0000785161-26-000144 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,437

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

SEC source: 0000785161-26-000113 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,803

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.21 to $106.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000113 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,469

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000947871-26-000160 · ownership.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,122.208

F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends.

SEC source: 0000785161-26-000002 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,450

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.79 to $103.08, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000002 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,104

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000100 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,085

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on October 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.19 to $123.24, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-25-000100 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,797

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019258 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,781

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on July 15, 2025

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.82 to $106.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-019258 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,448

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-013124 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,431

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-012489 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,007

F1 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on April 15, 2025.

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $98.23 to $98.24, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-012155 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,647

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $102.30. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000947871-25-000186 · ownership.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,284.197

F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends.

SEC source: 0001127602-25-001415 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,632

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on January 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $94.25 to $94.38, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-001415 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,257

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025668 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,241

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on October 15, 2024.

SEC source: 0001127602-24-025668 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,879

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020568 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,863

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on July 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.54 to $86.63, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-020568 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,437

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-014078 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,421

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-013017 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,443

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.45 to $79.67, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013017 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,032

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000947871-24-000104 · ownership.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,383.902

F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends.

SEC source: 0001127602-24-001544 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,019

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their directors fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on January 16, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $70.33 to $70.49, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-001544 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,554

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 16, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $71.45. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-026007 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,540

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their director fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on October 16, 2023.

SEC source: 0001127602-23-026007 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,536

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 16, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $63.77. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-020895 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,520

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on July 17,2023.

SEC source: 0001127602-23-020895 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,516

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $67.54. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-014813 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,501

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-013214 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,116

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on April 17, 2023.

SEC source: 0001127602-23-013214 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,112

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.39. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001209191-23-008406 · doc4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,554.8229

F1 · balance_after: The number of shares reported in Column 5 of Table I now includes 65.822912 shares received by the reporting person as stock dividends.

SEC source: 0001127602-23-001745 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,096

F2 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001745 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,101

F1 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on January 17, 2023.

SEC source: 0001127602-22-024170 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,085

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on October 17, 2022.

SEC source: 0001127602-22-024170 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,578

F1 · shares: Pursuant to restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-020040 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,709

F1 · shares: This number represents the purchase of (a) 492 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 4 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On July 20, 2022, the Company paid a dividend on common stock of $0.28 per share.

SEC source: 0001127602-22-019603 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,213

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 20, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $49.19. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-013835 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,189

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-22-012252 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,963

F2 · shares: This number represents the purchase of (a) 345 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 1 share associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On April 18, 2022, the Company paid a dividend on common stock of $0.28 per share.

SEC source: 0001127602-22-012252 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,617

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $71.41. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001209191-22-023286 · doc4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,510

SEC source: 0001127602-22-001942 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,612

F1 · shares: This number represents the purchase of shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan"). The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director.

SEC source: 0001127602-22-001735 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,213

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $61.63. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001543407-21-000053 · edgar.xml · nonDerivative · entry 3

Reidy Christopher R · CIK 0001290907 · CFO and EVP of Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,524

F3 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

SEC source: 0001543407-21-000053 · edgar.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · CFO and EVP of Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,579

F2 · shares: Represents shares withheld for payment of withholding taxes in connection with (A) vesting of the performance units referred to in footnote (1) and (B) the vesting of restricted stock units as previously reported on Table I.